Phase I/II clinical study of WT4869 peptide-based immunotherapy in patients with completely resected stage IA with vascular invasion, stage IB and stage II non-small cell lung cancer with WT1 antigen positive.

Trial Profile

Phase I/II clinical study of WT4869 peptide-based immunotherapy in patients with completely resected stage IA with vascular invasion, stage IB and stage II non-small cell lung cancer with WT1 antigen positive.

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 17 May 2016

At a glance

  • Drugs WT 4869 (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 13 Jul 2015 Planned End Date changed from 30 Sep 2021 to 6 jul 2015 as reported by University Hospital Medical Information Network - Japan.
    • 13 Jul 2015 Status changed from suspended to discontinued as reported by University Hospital Medical Information Network - Japan.
    • 14 Aug 2014 Status changed from recruiting to suspended as reported by University Hospital Medical Information Network - Japan.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top